Bio & The Business Of Aging With Life Biosciences' Jerry McLaughlin
The fountain of youth might be a fantasy, but the science behind manipulating the biology of aging has become big business. But does the investment community understand and embrace the concept? Will regulatory agencies view aging as an indication that warrants therapeutic review? And how does a legitimate biopharma company separate itself from the consumer-packaged anti-aging and cosmetic procedures markets? Business of Biotech welcomes Life Biosciences' CEO Jerry McLaughlin to address these questions and more.
Understanding the different types of pivots and when to use them can increase the chances of success for any life sciences company.
We all must do what’s best for our business, our teams (people), and ultimately the patient in a compliant manner. So, what happens if you prioritize one over the other?
Despite the hand-wringing that often accompanies conversations around corporate social responsibility (CSR), there is nothing controversial about basic human needs.
It’s no secret that finding pharma/biotech manufacturing talent is challenging, and the lack of workers is having a negative impact on productivity and growth. Here are four effective strategies for recruiting, training, educating, and retaining your workforce.
Cell And Gene Therapy Global Regulatory Report
Get a global overview of the cell and gene therapy regulatory landscape, including pipeline, late-stage, and approved products, covering cell, genetically modified cell, and gene therapies.
CONTRIBUTE TO LIFE SCIENCE LEADER
Think you have a good idea for an article that Life Science Leader readers would find valuable? Read these guidelines first before submitting your idea or your article to our editorial director.
|Connect With Life Science Leader:|